INT37191

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.32
First Reported 1986
Last Reported 2007
Negated 0
Speculated 0
Reported most in Body
Documents 2
Total Number 3
Disease Relevance 0.50
Pain Relevance 1.21

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

nucleolus (ABT1) RNA binding (ABT1) nucleus (ABT1)
DNA binding (ABT1)
ABT1 (Homo sapiens)
Pain Link Frequency Relevance Heat
Serotonin 2 100.00 Very High Very High Very High
Pain 2 100.00 Very High Very High Very High
opiate 1 98.08 Very High Very High Very High
analgesia 6 97.40 Very High Very High Very High
Analgesic 10 93.52 High High
Morphine 10 92.92 High High
Inflammation 2 62.08 Quite High
tail-flick 1 60.48 Quite High
Antinociceptive 1 55.28 Quite High
tolerance 4 25.00 Low Low
Disease Link Frequency Relevance Heat
Pain 2 100.00 Very High Very High Very High
Poisoning 4 90.24 High High
INFLAMMATION 2 62.08 Quite High
Disease 24 5.00 Very Low Very Low Very Low
Communicable Diseases 10 5.00 Very Low Very Low Very Low
Malaria 6 5.00 Very Low Very Low Very Low
Ovarian Cancer 4 5.00 Very Low Very Low Very Low
Zoonoses 4 5.00 Very Low Very Low Very Low
Heart Disease 2 5.00 Very Low Very Low Very Low
Hypertension 2 5.00 Very Low Very Low Very Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Synthetic peptides of 5-hydroxytryptophan (5-HTP), including N-acetyl-5-HTP-5-HTP amide (5-HTP-ACETYL-DP), specifically inhibit the binding of serotonin to serotonin binding protein. 5-HTP-ACETYL-DP also produces a long-lasting, opiate-sensitive analgesia following central, but not systemic administration.
serotonin binding protein Binding (binding) of associated with opiate, serotonin and analgesia
1) Confidence 0.32 Published 1986 Journal Peptides Section Abstract Doc Link 3494237 Disease Relevance 0 Pain Relevance 0.58
One compound derived from these studies, which binds to nicotinic acid receptors associated with pain pathways, the synthetic ABT 594 (Abbott Laboratories), is in Phase II clinical trials, and has generated a great deal of interest, as it has been shown to be 30–100 times more potent as an analgesic than morphine [10].
ABT Binding (binds) of associated with pain, analgesic and morphine
2) Confidence 0.04 Published 2007 Journal J Ethnobiol Ethnomedicine Section Body Doc Link PMC1847427 Disease Relevance 0.25 Pain Relevance 0.32
One compound derived from these studies, which binds to nicotinic acid receptors associated with pain pathways, the synthetic ABT 594 (Abbott Laboratories), is in Phase II clinical trials, and has generated a great deal of interest, as it has been shown to be 30–100 times more potent as an analgesic than morphine [10].
ABT Binding (binds) of associated with pain, analgesic and morphine
3) Confidence 0.03 Published 2007 Journal J Ethnobiol Ethnomedicine Section Body Doc Link PMC1847427 Disease Relevance 0.25 Pain Relevance 0.32

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox